1. Home
  2. SFL vs HROW Comparison

SFL vs HROW Comparison

Compare SFL & HROW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SFL Corporation Ltd

SFL

SFL Corporation Ltd

HOLD

Current Price

$10.45

Market Cap

1.5B

ML Signal

HOLD

Logo Harrow Inc.

HROW

Harrow Inc.

HOLD

Current Price

$41.36

Market Cap

1.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SFL
HROW
Founded
2003
1998
Country
Bermuda
United States
Employees
N/A
373
Industry
Marine Transportation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.4B
IPO Year
2004
N/A

Fundamental Metrics

Financial Performance
Metric
SFL
HROW
Price
$10.45
$41.36
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
8
Target Price
$12.00
$69.86
AVG Volume (30 Days)
1.4M
775.2K
Earning Date
05-13-2026
05-11-2026
Dividend Yield
7.05%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$31.62
Revenue Next Year
$13.07
$50.77
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.73
$28.54
52 Week High
$12.94
$54.98

Technical Indicators

Market Signals
Indicator
SFL
HROW
Relative Strength Index (RSI) 35.21 62.90
Support Level $9.83 $40.61
Resistance Level $11.24 $41.94
Average True Range (ATR) 0.33 2.13
MACD -0.05 0.56
Stochastic Oscillator 15.11 72.82

Price Performance

Historical Comparison
SFL
HROW

About SFL SFL Corporation Ltd

SFL Corp Ltd is an international ship-owning and chartering company. The company is engaged in transporting crude oil and oil products, dry bulk and containerized cargoes, freight of rolling cargo, and offshore drilling and related activities. The company operates as a single reportable segment, generating revenue from long-term, fixed-rate charters. Its Additional revenue sources include sales-type lease interest income, voyage charter and pool revenues, and drilling contract revenues.

About HROW Harrow Inc.

Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.

Share on Social Networks: